Skip to main content

Bodhi Tree Biotechnology Inc

corporate_fare Company Profile

Bodhi Tree Biotechnology Inc

BDTB·OTC·Trade & Services·CIK 0002041531

Bodhi Tree Biotechnology Inc. is an early-stage consulting company incorporated in Delaware on December 12, 2023. The company focuses on providing plant-based menu design, recipe development, and vegetarian diet consulting services from its executive office in Danville, California. Its services align with consumer interest in flexitarian, vegetarian, and organic lifestyles, addressing the demand for healthier recipe options and sustainable dietary habits. The company's strategy involves introducing vegetarian lifestyle attributes and connecting with consumers who value nutritious, sustainably sourced, and plant-based meals and recipes. It focuses on design and product development, including creating distinctive flavor profiles for vegetarian consumers, and developing new recipes and menus to meet market trends and demand for healthy plant-based options. Bodhi Tree Biotechnology also offers dietary consulting to help customers integrate vegetarian principles into their daily nutrition. The company's President and CEO, Xiaohang Wang, has over 13 years of experience in the health products industry, and its CFO, Juan Ye, has served in that capacity at another company since 2019. As an early-stage company, its operations are limited, and it is not currently subject to environmental regulations. Its vegetarian menu and recipe design services are provided on a project-by-project basis, focusing on plant-based menus and vegetarian recipes that meet customer preferences for healthier and more sustainable food options.

Bodhi Tree Biotechnology Inc (OTC:BDTB) is a publicly traded company in the Trade & Services sector. Wiseek has independently scored 2 items for BDTB at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-08-14, rated 8/10. Across its 2 most recent items scored 7 or higher, the top rating is 8/10, with 2 rated 8 or above. Recent SEC coverage for BDTB spans 10-Q.

Recent high-impact activity:

  • Cash Plunges 96% to $3,986; Survival Hinges on Shareholder Loan Promise
  • Bodhi Tree Biotechnology Reports Critical Liquidity, Material Control Weaknesses, and Extreme Customer Concentration

Financial Snapshot

Fiscal year ended September 30, 2025
Revenue
$17K
Net Income
-$149.67K
Diluted EPS
-$0.01
Op. Cash Flow
-$150.17K
Operating Income
-$147.62K
Cash & Equivalents
$109.4K
Debt / Equity
0.00×
Net Margin
-8.80×
Shares Outstanding
25.44M sh
Source: 10-K · filed 2025-12-29 · accession 0001829126-25-010312

Short Interest & Short Volume

On October 2, 2026, 46.4% of BDTB volume reported to FINRA trade-reporting facilities was marked short.

Daily short volume (FINRA facilities)46.4% of 18,650 shares on October 2, 2026

Daily short sale volume covers trades reported to FINRA trade-reporting facilities and is not the same as short interest (bi-monthly reported positions). Source: FINRA — FINRA is the owner and source of this short interest and short sale volume data; it may not be redistributed.

$0.282 +0.13% today
52-week range · as of 2026-08-14 $0.06 – $0.282
Volume
18.6K (0.6× avg)
3-mo avg 30K
Live data · 2026-10-05 02:49 UTC · Market closed

show_chartPrice Chart

Loading chart...

feed BDTB - Latest Insights

BDTB
Aug 14, 2026, 4:16 PM EDT
Filing Type: 10-Q
Importance Score:
8
Price at Filing: $0.200
Real-time Price: $0.282 info
Change: +$0.082 (+41%) info
Market Cap: N/A info
BDTB
May 14, 2026, 10:26 AM EDT
Filing Type: 10-Q
Importance Score:
8
Price at Filing: $0.200
Real-time Price: $0.282 info
Change: +$0.082 (+41%) info
Market Cap: N/A info
Research tools: Filing Impact Index Dilution Tracker Split Calendar Open Datasets